EUCTR2009-013272-47-NL进行中（未招募）1 期
International Study to Predict Optimized Treatment - in Attention-Deficit and Hyperactivity Disorder - iSPOT-A
BRC operations Pty. Ltd0 个研究点目标入组 722 人开始时间: 2011年11月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 722
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria for ADHD Subjects
- •Meet DSM-IV criteria for primary diagnosis of ADHD at study entry, as determined by The Mini International Neuropsychiatric Interview for Children and Adolescents (MINI Kid).
- •Have an Attention Deficit / Hyperactivity Disorder Rating Scale (ADHD-RS IV) score of 6 or higher for inattention and/or hyperactivity-impulsivity.
- •Subject is a candidate for methylphenidate.
- •Stimulant naïve or stimulant free (defined as no stimulant medication in the previous 7 days).
- •Males and females 6-17 years of age
- •Subjects who are fluent and literate in English or Dutch (the languages in which the psychological assessments have been validated).
- •Subjects who have signed an informed consent or assent form where required and/or whose parent or legal guardian has provided written informed consent.
- •Inclusion Criteria for Control Subjects
- •Male and females 6-17 years of age.
- •Subjects who are fluent and literate in English or Dutch (the languages in which the psychological assessments have been validated).
- •Subjects who have signed an informed consent or assent form where required and/or whose parent or legal guardian has provided written informed consent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria for ADHD Subjects
- •Known contra-indication to the use of methylphenidate.
- •Pregnancy and females of child bearing potential who are not using a form of contraception and are at risk of becoming pregnant during the study.
- •Known medical condition, disease or neurological disorder which might, in the opinion of investigator/s, interfere with the assessments to be made in the study or put ADHD patients at increased risk when exposed to optimal doses of the drug treatment (including, but not limited to, anxiety, tension or agitation; glaucoma; motor tics; family history or diagnosis of Tourette’s syndrome; treatment with monoamine oxidase inhibitors, and within 14 days following discontinuation of monoamine oxidase inhibitors; serious structural cardiac abnormalities,
- •cardiomyopathy, serious heart rhythm abnormalities, or other serious problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug; hypertension, heart failure, recent myocardial infarction, ventricular arrhythmia; psychotic disorder, bipolar disorder, family history of suicide, bipolar disorder and depression; prior history of seizures or prior EEG abnormalities; allergy to any of the inactive ingredients in Ritalin).
- •History of physical brain injury or blow to the head that resulted in loss of consciousness of greater than 5 minutes.
- •Prior treatment with methylphenidate or any other stimulant medication in the past 7 days.
- •Known past or present substance dependence, including alcohol, as determined by The Mini International Neuropsychiatric Interview for Children and Adolescents (MINI Kid).
- •Participation in an investigational study within four months of the baseline visit (excluding follow-up studies in which the test drug/device has been registered in a major market) in which subjects have received an experimental drug/device that could affect the primary end points of this study.
- •Subjects who, in the opinion of the investigator, have a severe impediment to vision, hearing and/or hand movement, which is likely to interfere with their ability to complete the testing batteries.
- •Subjects who, in the opinion of the investigator, are unable and/or unlikely to comprehend and follow the study procedures and instructions.
- •Presence of any other co-morbid primary DSM IV disorder (other than conduct disorder or oppositional defiant disorder).
- •Known history of hypersensitivity and/or anaphylaxis to methylphenidate.
- •Exclusion Criteria for Control Subjects
- •Current or previous diagnosis of ADHD or any other psychiatric diagnosis.
- •Pregnancy and females of child bearing potential who are not using a form of contraception and are at risk of becoming pregnant during the study.
- •Known medical condition, disease or neurological disorder which might, in the opinion of investigator/s, interfere with the assessments to be made in the study or put subjects at increased risk (including, but not limited to, anxiety, tension or agitation; glaucoma; motor tics; family history or diagnosis of Tourette’s syndrome; treatment with monoamine oxidase inhibitors, and within 14 days following discontinuation of monoamine oxidase inhibitors; serious structural
- •cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug; hypertension, heart failure, recent myocardial infarction, ventricu
研究者
相似试验
招募中
4 期
International Study to Predict Optimized Treatment - in DepressioACTRN12608000476336Brain Resource2,688
招募中
4 期
International Study to Predict Optimised Treatment in Children and Adolescents with Attention Deficit/Hyperactivity DisorderAttention Deficit/Hyperactivity Disorder (ADHD) in children and adolescentsMental Health - Other mental health disordersACTRN12609000271202Brain Resource Pty Ltd1,344
进行中（未招募）
1 期
International Study to Predict Optimised Treatment - in DepressioniSPOT-D - iSPOT-DPatients suffering from major depressive disorder (MDD) as well as healthy control participants. Only patients will receive medication which will be 'treatment as usual'.EUCTR2008-004122-17-NLBRC operations Pty. Ltd.2,163
已完成
不适用
An international study of improving treatment for the most severely ill with schizophreniaMental and Behavioural DisordersSchizophreniaISRCTN41543404Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)100
尚未招募
不适用
Multicenter clinical study on the optimal treatment protocol and outcome of cough variant asthma with Chinese and Western Medicinecough variant asthmaITMCTR2200005741The First Affiliated Hospital of Zhejiang Chinese Medical University